Outlook Therapeutics Inc (OTLK)

[conix]

Macular Degeneration is a growing health cost for medical systems across the globe. Injecting pharmaceuticals into the eye is not the best way to achieve a high level of patient compliance.

Medicare and Medicaid really needs to find an efficacious treatment to slow the progression of Age-Related Macular Degeneration (AMD) that is cost effective--and easy to deliver.

Eyedrop formulations of Metformin, the broadly used diabetes drug, apparently holds some promise --according to the National Eye Institute which just entered into a clinical trial agreement with a small biotech company (CUBT).

But there is a major push in this field for the NIH to fund clinical trials in this huge market. It cost infinitely more to pay for caregivers of blind pagients vs. slowing the progression to blindness.